Old Web
English
Sign In
Acemap
>
Paper
>
P1.14-18 ALK Inhibitor Sequencing and Outcomes Among ALK-Positive (ALK+) NSCLC Patients in the US Community Oncology Setting
P1.14-18 ALK Inhibitor Sequencing and Outcomes Among ALK-Positive (ALK+) NSCLC Patients in the US Community Oncology Setting
2019
David M. Waterhouse
Janet L. Espirito
Marc Chioda
B. Baidoo
Jack Mardekian
Nicholas J. Robert
Elizabeth T. Masters
Keywords:
Oncology
ALK-Positive
ALK inhibitor
Medicine
Internal medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]